Metabolic dysfunction-associated steatohepatitis (MASH) is a growing clinical challenge due to its increasing prevalence, complex pathophysiology, and strong association with comorbid conditions such as cardiovascular disease and obesity. Evolving diagnostic criteria, risk stratification tools, and new therapeutic options require health …
GLP-1 receptor agonists (GLP-1 RAs) are a top-tier recommendation for patients with type 2 diabetes (T2D), especially those with concomitant cardiovascular disease (CVD), chronic kidney disease (CKD), or obesity. Backed by robust clinical trial data and endorsed across leading guidelines, …
Mycophenolate-containing medications are widely used to prevent organ rejection in transplant recipients and to treat (off label) some autoimmune conditions such as lupus; however, use of these immunosuppressive agents during pregnancy is linked to a significantly increased risk of miscarriage …
GLP-1 receptor agonists (GLP-1 RAs) have redefined the standard of care for type 2 diabetes (T2D), especially in patients with cardiovascular disease (CVD), chronic kidney disease (CKD), obesity, or metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH). These innovative therapies …
Underserved patient populations often face significant health disparities rooted in unaddressed social drivers of health (SDOH), such as food insecurity, housing instability, and limited access to care. These social needs directly contribute to poor health outcomes and preventable health complications. …
